Forsta AP Fonden Sells 1,200 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Forsta AP Fonden lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 2.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,700 shares of the pharmaceutical company's stock after selling 1,200 shares during the quarter. Forsta AP Fonden's holdings in Vertex Pharmaceuticals were worth $23,638,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Foster Victor Wealth Advisors LLC boosted its stake in shares of Vertex Pharmaceuticals by 14.2% in the 4th quarter. Foster Victor Wealth Advisors LLC now owns 24,588 shares of the pharmaceutical company's stock valued at $10,376,000 after purchasing an additional 3,062 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at $44,000. Williams & Novak LLC acquired a new position in Vertex Pharmaceuticals during the 4th quarter worth about $277,000. Patriot Financial Group Insurance Agency LLC lifted its position in Vertex Pharmaceuticals by 2.4% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 3,466 shares of the pharmaceutical company's stock worth $1,396,000 after buying an additional 82 shares in the last quarter. Finally, Stonegate Investment Group LLC lifted its position in Vertex Pharmaceuticals by 0.6% during the 4th quarter. Stonegate Investment Group LLC now owns 6,509 shares of the pharmaceutical company's stock worth $2,621,000 after buying an additional 41 shares in the last quarter. Institutional investors own 90.96% of the company's stock.

Analysts Set New Price Targets

VRTX has been the topic of several research reports. Canaccord Genuity Group upped their price target on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a "sell" rating in a research report on Wednesday, November 6th. Stifel Nicolaus boosted their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a report on Monday, December 16th. BMO Capital Markets dropped their price objective on Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating for the company in a report on Friday, December 20th. Piper Sandler dropped their price objective on Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating for the company in a report on Monday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $494.76.

Vertex Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ VRTX traded up $0.84 during trading hours on Wednesday, hitting $441.52. The company had a trading volume of 1,025,800 shares, compared to its average volume of 1,495,690. The stock has a market capitalization of $113.70 billion, a P/E ratio of -221.87, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The firm's 50 day moving average is $434.75 and its 200-day moving average is $463.64.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.67 EPS. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.